March 4, 2013 / 11:26 PM / in 4 years

AcelRx pain treatment meets late-stage study goal

1 Min Read

(Reuters) - AcelRx Pharmaceuticals Inc said its experimental drug-device combination for post-operative pain met the main goal of a late-stage study on patients who have undergone major open abdominal surgery.

AcelRx shares jumped 10 percent to $5.49 after the bell on Monday.

The top-line results reported from a 178-patient study of AcelRx's sublingual Sufentanil NanoTab PCA system showed that the patient-controlled drug-device combination helped reduce pain significantly compared with a placebo, the company said.

Reporting by Zeba Siddiqui in Bangalore; Editing by Roshni Menon

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below